SG11201406359TA - Improving resistance to skeletal muscle fatigue - Google Patents

Improving resistance to skeletal muscle fatigue

Info

Publication number
SG11201406359TA
SG11201406359TA SG11201406359TA SG11201406359TA SG11201406359TA SG 11201406359T A SG11201406359T A SG 11201406359TA SG 11201406359T A SG11201406359T A SG 11201406359TA SG 11201406359T A SG11201406359T A SG 11201406359TA SG 11201406359T A SG11201406359T A SG 11201406359TA
Authority
SG
Singapore
Prior art keywords
skeletal muscle
muscle fatigue
improving resistance
improving
resistance
Prior art date
Application number
SG11201406359TA
Other languages
English (en)
Inventor
Fady Malik
Jeffrey R Jasper
Adam Kennedy
Darren Hwee
Original Assignee
Cytokinetics Inc
Fady Malik
Jeffrey R Jasper
Adam Kennedy
Darren Hwee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Fady Malik, Jeffrey R Jasper, Adam Kennedy, Darren Hwee filed Critical Cytokinetics Inc
Publication of SG11201406359TA publication Critical patent/SG11201406359TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201406359TA 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue SG11201406359TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US201261735809P 2012-12-11 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
SG11201406359TA true SG11201406359TA (en) 2014-11-27

Family

ID=49328282

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704166RA SG10201704166RA (en) 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue
SG11201406359TA SG11201406359TA (en) 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201704166RA SG10201704166RA (en) 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue

Country Status (15)

Country Link
US (2) US20150250784A1 (enExample)
EP (1) EP2836590A4 (enExample)
JP (2) JP6352244B2 (enExample)
KR (1) KR102163931B1 (enExample)
CN (2) CN111840294A (enExample)
AU (3) AU2013245917A1 (enExample)
BR (1) BR112014025251B1 (enExample)
CA (1) CA2869675C (enExample)
EA (1) EA032480B1 (enExample)
HK (1) HK1206389A1 (enExample)
IL (2) IL234886A (enExample)
MX (1) MX2014012179A (enExample)
PH (1) PH12014502286A1 (enExample)
SG (2) SG10201704166RA (enExample)
WO (1) WO2013155262A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
RS63018B1 (sr) * 2014-04-29 2022-04-29 Cytokinetics Inc Metode za smanjenje opadanja vitalnog kapaciteta
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2017002853A (es) 2014-09-09 2018-01-12 Astellas Pharma Inc Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria.
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
BR112022000281A2 (pt) 2019-07-23 2022-02-22 Amorphical Ltd Carbonato de cálcio amorfo para aprimorar o desempenho atlético
AR124008A1 (es) 2020-11-06 2023-02-01 Cytokinetics Inc 1,4-diazepanonas bicíclicas y sus usos terapéuticos
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EA201001224A1 (ru) * 2008-02-04 2011-08-30 Цитокинетикс, Инкорпорейтед Химические соединения, композиции и способы их использования
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
MX354965B (es) * 2012-04-02 2018-03-27 Cytokinetics Inc Metodo para mejorar la funcion del diafragma.

Also Published As

Publication number Publication date
EA201491666A1 (ru) 2015-03-31
CN104395458A (zh) 2015-03-04
JP6352244B2 (ja) 2018-07-04
CN111840294A (zh) 2020-10-30
US20150250784A1 (en) 2015-09-10
KR20160046694A (ko) 2016-04-29
MX2014012179A (es) 2015-07-14
SG10201704166RA (en) 2017-06-29
EP2836590A4 (en) 2016-04-13
JP2015516392A (ja) 2015-06-11
WO2013155262A2 (en) 2013-10-17
BR112014025251B1 (pt) 2021-03-02
CA2869675C (en) 2022-06-14
PH12014502286B1 (en) 2014-12-15
HK1206389A1 (en) 2016-01-08
WO2013155262A3 (en) 2013-12-27
IL250473A0 (en) 2017-03-30
AU2018200930A1 (en) 2018-03-01
CA2869675A1 (en) 2013-10-17
KR102163931B1 (ko) 2020-10-12
JP6535727B2 (ja) 2019-06-26
JP2018048209A (ja) 2018-03-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
PH12014502286A1 (en) 2014-12-15
AU2019268177A1 (en) 2019-12-12
US20190167676A1 (en) 2019-06-06
AU2013245917A1 (en) 2014-10-23
IL234886A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
SG10201704166RA (en) Improving resistance to skeletal muscle fatigue
IL226745A0 (en) Simulates a physical heart
EP2812081A4 (en) TRAINING MAT
EP2818214A4 (en) EXERCISE BICYCLE
SG11201501802VA (en) Implement for training facial muscle
HUE043603T2 (hu) Sejtmentesített izommátrix
ZA201504845B (en) Trampolines
GB201316224D0 (en) Improvements in or relating to stairlifts
GB201212069D0 (en) Predicting resistance to disease
PL2684481T3 (pl) Sportowy lub fitnessowy kijek treningowy
GB2499828B (en) Exercise bar
AP2015008378A0 (en) Improvements relating to buoyancy-supported risers
GB201215007D0 (en) Improvements in or relating to luminaires
GB201211746D0 (en) Improvements in or relating to exercise devices
GB2510810B (en) Improvements in or relating to stairlifts
GB201314092D0 (en) Improvements in or relating to garments
GB2503199B (en) Improvements in or relating to stairlifts
GB2499408B (en) Improvements in or relating to stairlifts
GB2508793B (en) Improvements in or relating to hardware
GB201220690D0 (en) Improvements relating to pasteurisation
GB2499409B (en) Improvements in or relating to stairlifts
GB201221194D0 (en) hand exerciser
GB201216324D0 (en) Hand exerciser
GB201214543D0 (en) Hand exerciser
GB201210951D0 (en) Hand exerciser